HEBP2-governed glutamine competition between tumor and macrophages dictates immunotherapy efficacy in triple-negative breast cancer

Authors:

Abstract
No abstract available
Funding Information
  • National Natural Science Foundation of China (92159301)
  • National Natural Science Foundation of China (82425044)
  • National Natural Science Foundation of China (U24A20736)
  • National Natural Science Foundation of China (82373167)
  • National Natural Science Foundation of China (82341003)
  • Beijing Xisike Clinical Oncology Research Foundation (Y-MSDZD2022-0489)
  • Shanghai Municipal Health Commission

This publication has 42 references indexed in Scilit: